, Volume 89, Issue 4, pp 427-428
Date: 28 Aug 2009

Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Dear Editor,

5-Azacitidine has become the standard of care for patients with high-risk myelodysplastic syndromes (MDS), because it has shown an impressive survival benefit compared to three conventional care regimens [1]. In the pivotal trial by Fenaux et al. [1], 5-azacitidine was administered subcutaneously (s.c.) for 7 days. Other trials [2] have tested administration over a cumulative period of up to 10 days. In general, in case of response, the treatment needs to be continued until disease progression. Although an oral formulation is under development [3] and i.v. administration is also possible, the majority of patients receive the drug s.c., according to the phase III trial that was the basis for approval in the European Union. The drug appears to be very well tolerated, however, and in agreements with a recent report in this journal [4], local injection site skin reactions are observed within the most common nonhematological adverse events. This side effect, although usually com ...